Different Cytotoxic Effects of Cisplatin on Pancreatic Ductal Adenocarcinoma Cell Lines

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2025 Jan 8

PMID 39769425

Authors

Antonella Muscella

Luca G Cossa

Erika Stefano

Gianluca Rovito

Michele Benedetti

Francesco P Fanizzi

Santo Marsigliante

Affiliations

Soon will be listed here.

Abstract

This study examined the response to cisplatin in BxPC-3, Mia-Paca-2, PANC-1, and YAPC pancreatic cancer lines with different genotypic and phenotypic characteristics, and the mechanisms associated with their resistance. BxPC-3 and MIA-PaCa-2 cell lines were the most sensitive to cisplatin, while YAPC and PANC-1 were more resistant. Consistently, in cisplatin-treated BxPC-3 cells, the cleavage patterns of pro-caspase-9, -7, -3, and PARP-1 demonstrated that they were more sensitive than YAPC cells. The autophagic pathway, promoting cisplatin resistance, was active in BxPC-3 cells, as demonstrated by the time-dependent conversion of LC3-I to LC3-II, whereas it was not activated in YAPC cells. In cisplatin-treated BxPC-3 cells, Bcl-2 decreased, while Beclin-1, Atg-3, and Atg-5 increased along with JNK1/2 phosphorylation. Basal levels of phosphorylated ERK1/2 in each cell line were positively correlated with cisplatin IC50 values, and cisplatin caused the activation of ERK1/2 in BxPC-3 and YAPC cells. Furthermore, ERK1/2 pharmacological inactivation increased cisplatin lethality in both BxPC-3 and YAPC cells, suggesting that p-ERK1/2 may be related to cisplatin resistance of PDAC cells. Different mechanisms and strategies are generally required to acquire drug resistance. Here, we partially explain the other response to cisplatin of BxPC-3 and YAPC cell lines by relating it to the role of ERK pathway.

References

Trapani A, Corbo F, Stefano E, Capobianco L, Muscella A, Marsigliante S . Oxidized Alginate Dopamine Conjugate: A Study to Gain Insight into Cell/Particle Interactions. J Funct Biomater. 2022; 13(4). PMC: 9680352. DOI: 10.3390/jfb13040201. View

Hashimoto D, Blauer M, Hirota M, Ikonen N, Sand J, Laukkarinen J . Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs. Eur J Cancer. 2014; 50(7):1382-90. DOI: 10.1016/j.ejca.2014.01.011. View

Lili L, Matyunina L, Walker L, Daneker G, McDonald J . Evidence for the importance of personalized molecular profiling in pancreatic cancer. Pancreas. 2014; 43(2):198-211. PMC: 4206352. DOI: 10.1097/MPA.0000000000000020. View

Jameson G, Borazanci E, Babiker H, Poplin E, Niewiarowska A, Gordon M . Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial. JAMA Oncol. 2019; 6(1):125-132. PMC: 6777241. DOI: 10.1001/jamaoncol.2019.3394. View

Yamada T, Okajima F, Adachi M, Ohwada S, Kondo Y . Growth dependency of a new human pancreatic cancer cell line, YAPC, on autocrine interleukin-1alpha stimulation. Int J Cancer. 1998; 76(1):141-7. DOI: 10.1002/(sici)1097-0215(19980330)76:1<141::aid-ijc22>3.0.co;2-e. View

Ma T, Chen W, Zhi X, Liu H, Zhou Y, Chen B . USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy. Cancer Lett. 2018; 436:129-138. DOI: 10.1016/j.canlet.2018.08.010. View

Zeh H, Bahary N, Boone B, Singhi A, Miller-Ocuin J, Normolle D . A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clin Cancer Res. 2020; 26(13):3126-3134. PMC: 8086597. DOI: 10.1158/1078-0432.CCR-19-4042. View

Muller M, Friess H, Koninger J, Martin D, Wente M, Hinz U . Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg. 2007; 195(2):221-8. DOI: 10.1016/j.amjsurg.2007.02.026. View

Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H . Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011; 25(7):717-29. PMC: 3070934. DOI: 10.1101/gad.2016111. View

10.

El-Rayes B, Zalupski M, Shields A, Vaishampayan U, Heilbrun L, Jain V . Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol. 2003; 21(15):2920-5. DOI: 10.1200/JCO.2003.03.022. View

11.

Li B, Yang J, Lu Z, Liu B, Liu F . A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway. J BUON. 2019; 24(2):739-745. View

12.

Cid-Arregui A, Juarez V . Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol. 2015; 21(31):9297-316. PMC: 4541382. DOI: 10.3748/wjg.v21.i31.9297. View

13.

Muscella A, Marsigliante S, Verri T, Urso L, Dimitri C, Botta G . PKC-epsilon-dependent cytosol-to-membrane translocation of pendrin in rat thyroid PC Cl3 cells. J Cell Physiol. 2008; 217(1):103-12. DOI: 10.1002/jcp.21478. View

14.

Bergman A, Pinedo H, Peters G . Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 2002; 5(1):19-33. DOI: 10.1016/s1368-7646(02)00002-x. View

15.

DAndrea A, Grompe M . The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003; 3(1):23-34. DOI: 10.1038/nrc970. View

16.

Shimizu S, Yoshida T, Tsujioka M, Arakawa S . Autophagic cell death and cancer. Int J Mol Sci. 2014; 15(2):3145-53. PMC: 3958902. DOI: 10.3390/ijms15023145. View

17.

Girolimetti G, Balena B, Cordella P, Verri T, Eusebi L, Bozzetti M . Characterization of Chemoresistance in Pancreatic Cancer: A Look at MDR-1 Polymorphisms and Expression in Cancer Cells and Patients. Int J Mol Sci. 2024; 25(15). PMC: 11312866. DOI: 10.3390/ijms25158515. View

18.

Adiseshaiah P, Crist R, Hook S, McNeil S . Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol. 2016; 13(12):750-765. DOI: 10.1038/nrclinonc.2016.119. View

19.

Kong F, Liu X, Zhou Y, Hou X, He J, Li Q . Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. Int J Biochem Cell Biol. 2020; 122:105731. DOI: 10.1016/j.biocel.2020.105731. View

20.

de Sousa Cavalcante L, Monteiro G . Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014; 741:8-16. DOI: 10.1016/j.ejphar.2014.07.041. View